📊 Key financial figures (FY 2024/25) - $SOON (+3,27%)
- SalesIncrease of 6.6 % to CHF 3.87 billion, exceeding analysts' estimates of CHF 3.84 billion.
- Adjusted EBITA: Increase of 4.7 % to CHF 807.8 million, slightly above the consensus of CHF 804.9 million.
- Gross marginImproved to 71.9 %, an increase of 50 basis points compared to the previous year.
- Organic growth: 4,5 %
- Contribution from acquisitions: 1,4 %
These results reflect a solid performance, particularly in hearing aids, supported by the launch of a new product platform in August.
🔮 Outlook for the 2025/26 financial year
- Sales growthExpected between 5% and 9% at constant exchange rates.
- EBITA growthForecast between 14% and 18%, also at constant exchange rates and adjusted for special effects, but including restructuring costs.
These forecasts are based on the assumption that no additional significant customs duties will be introduced.
👥 Management change
CEO Arnd Kaldowski will step down in September 2025 for personal reasons. Eric Bernard, former CEO of WS Audiology, will take over the position from October 2025.
📈 Market reaction
Sonova's share price performed positively following the publication of the results, indicating investor confidence in the company's strategic direction and future growth prospects.
Overall, Sonova presented solid annual results with a promising outlook for the coming financial year, supported by innovative products and a strategic realignment in management.
Competitors:
$DEMANT (+2,54%) /$AMP (-2,75%) / $GN (+2,3%)
Own investment:
Total: CHF 1,045.72 (x4 shares)
Invested: CHF 936.80
Price gain: CHF 108.92 (11.63 %)
Realized gain: -
Total return: 113.07 CHF
Buy In: 234.20 CHF
Invest is currently not being increased. But I am a big fan, $SOON (+3,27%) to hold. Hearing aids are not only relevant for the ageing population, but also increasingly the protection of hearing and "perfect enjoyment of sound" as a luxury movement.
